Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.

Jing Voon ChenJames C GahnJeffrey NesheimPaul N Mudd

Published in: PharmacoEconomics (2022)

Vibegron may address unmet needs in treating OAB and is a useful addition to health plans while minimizing risks of anticholinergic AEs, ACB, and drug-drug interactions, which may partially offset increased pharmacy costs.

Keyphrases

healthcare
public health
human health
mental health
health insurance
risk assessment
health information
emergency department
climate change